

CURRICULUM VITAE

DATE: November 30, 2020

NAME: MACHTELD ELISABETH HILLEN

PRESENT TITLE: Associate Professor
Chief of Service
Neurology Residency Program Director
Director Adult Neurology Clinic

OFFICE ADDRESS: 90 Bergen Street
DOC 5200
Newark, NJ, 07103

TELEPHONE NUMBER/E-MAIL ADDRESS: machteld.hillen@rutgers.edu

CITIZENSHIP: USA, Dutch

EDUCATION:

- A. Undergraduate Education
State University of Groningen
Groningen, the Netherlands
Doctorandus der Geneeskunde August 31, 1992
- B. Graduate and Professional
State University of Groningen
Groningen, the Netherlands
Medical Degree June 29, 1995

POSTGRADUATE TRAINING:

- A. Internship and Residencies
Englewood Hospital, Englewood, NJ
Internal Medicine
07/96-06/97

State University of New York-Health Science Center at Brooklyn, Brooklyn, New York
Neurology
07/97-06/98

University of Medicine and Dentistry of New Jersey-New Jersey Medical School,
Newark, NJ
Neurology
07/98-06/00
- B. Fellowship
University of Medicine and Dentistry of New Jersey-New Jersey Medical School,
Newark, NJ
Neuroimmunology/Multiple Sclerosis
07/00-06/02
- C. Postdoctoral Appointments
None

MILITARY: none

ACADEMIC APPOINTMENTS:

Department of Neurology and Neurosciences
Rutgers-New Jersey Medical School
Associate Professor
07/13-present

Department of Neurology and Neurosciences
UMDNJ-New Jersey Medical School
Assistant Professor
07/04-06/13

HOSPITAL APPOINTMENTS:

Department of Neurology
University Hospital
Chief of Service
06/20-present

Department of Neurology
University Hospital
Attending Neurologist
07/04-present

Department of Medicine
Rahway Hospital
Attending Neurologist
12/19-present

Department of Medicine
Overlook Hospital
Attending Neurologist
08/02-12/06

Department of Neurology
East Orange Veterans Administration
Attending Physician without compensation
12/00-06/02

Department of Medicine
Holy Name Hospital
Attending Neurologist at the Bernard Gimbel Multiple Sclerosis Center
10/00-06/02

OTHER EMPLOYMENT OR MAJOR VISITING APPOINTMENTS: none

PRIVATE PRACTICE

Summit Medical Group, Summit, NJ
08/02-06/04

LICENSURE: Medical Doctor 25MA07102500 06/30/2019

DRUG LICENSURE:

CDS: D07832900 10/31/2016
DEA: BH6925486 10/31/2018

CERTIFICATION: American Board of Neurology and Psychiatry Neurology 51287 Original Certification 05/02, recertified in 2012, currently in Maintenance of Certification (MOC).

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

Huntington Study Group
Member
2013-present

American Academy of Neurology
Consortium of Neurology Program Directors
Member
2008-present

Association of University Professors in Neurology
Member
2004-present

American Academy of Neurology
Active Member
1998-present

American Academy of Neurology
Consortium of Clerkship Directors
Member
2004-2010

HONORS AND AWARDS:

Nomination Golden Apple Award for Teaching
Nominated by NJMS Class of 2018
03/24/2018

Nomination 2016 AAN Program Director Recognition Award
Nominated by the Neurology Chief Residents
04/15/2016

Nomination Golden Apple Award for Teaching
Nominated by NJMS Class of 2015
03/29/2014

Plaque of appreciation for your willingness to go above or beyond in helping guide residents
Awarded by the Class of 2013
06/13/13

The Raymond A. Troiano Golden Hammer Award in recognition of teaching excellence
Awarded by the neurology residents
06/21/12

Advancing Hope Award
Awarded by the NJ Chapter of the Huntington's Disease Society of America to the staff of the Samuel L. Baily University Huntington's Disease Center
05/20/12

Appreciation for Outstanding Leadership as Neurology Residency Program Director
Awarded by the Class of 2011
06/16/2011

A. B. Baker Teaching Recognition Award for excellence in neurologic education,
Awarded by the American Academy of Neurology
04/27/2009

Certificate of Excellence in recognition of outstanding teaching
Awarded by the neurology residents
06/24/2009

Nomination Golden Apple Award for Teaching
Nominated by NJMS Class of 2009
04/04/2009

Golden Hammer Award in recognition of teaching excellence
Awarded by the neurology residents
06/2007

BOARDS OF DIRECTORS/TRUSTEES POSITIONS: none

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

SERVICE ON MAJOR COMMITTEES:

- A. International: none
- B. National: Neurology on the Hill, Washington DC, 3/26/18-2/27/18
 Advisory Committee for Treatment of Late Stage Huntington's
 Disease, Lundbeck 3/31/12
- C. Rutgers-New Jersey Medical School
 Resident Performance Enhancement Committee, 3/18-present
 CAP2, 9/17-9/18
 Duty Hour Surveillance Subcommittee, Chair, 8/14-present
 Graduate Medical Education Committee, 07/13-present
- D. University of Medicine and Dentistry of New Jersey-New Jersey Medical School:
 Graduate Medical Education Committee, 08/08-06/13
 Institutional Setting Committee, 01/12-03/13
 Search Committee Psychiatry Chair, 11/11-10/12
 Clinical Curriculum Committee, 07/04-05/10
- E. The University Hospital:
 ACS Quality Sub-Committee, 06/17-07/18
 Ambulatory Care Committee, 10/06-07/18
 Epic Steering Committee, 02/12-07/17
 Charity Care Management Team, 10/10-03/11
- F. Department of Neurology and Neurosciences:
 Metrics Review Committee 06/2017-present
 Clinical Competency Committee 07/13-present
 Residency Curriculum Review Committee 07/04-present
 Residency Selection Committee 07/04-present
- G. Editorial Boards: none
- H. *AdHoc* Reviewer: none

SERVICE ON GRADUATE SCHOOL COMMITTEES: none

SERVICE ON HOSPITAL COMMITTEES: See Above

SERVICE TO THE COMMUNITY:

Key Note Speaker
The Sharing and Caring Educational Conference of the New Jersey Chapter of the Huntington's
Disease Society of America, Edison, NJ, 05/17

Second Annual Dinner with the Doctors, Keynote Speaker and Expert Panelist
Huntington's Disease Society of America (HDSA), New Brunswick, NJ, 08/14

Ask the Doctor, Expert Panelist
The Sharing and Caring Educational Conference of the New Jersey Chapter of the Huntington's
Disease Society of America, Somerset, NJ, 05/12

SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE: none

SPONSORSHIP OF POSTDOCTORAL FELLOWS: none

TEACHING RESPONSIBILITIES:

- A. Lectures or Course Directorships
1. Rutgers-New Jersey Medical School,
Neurology Residency Associate Program Director, 08/20-present
 2. Rutgers-New Jersey Medical School,
Neurology Residency Program Director, 08/08-08/20
 3. Rutgers-New Jersey Medical School,
Clerkship Co-Director Psychiatry/Neurology Clerkship, 06/06-05/10
 4. Rutgers-New Jersey Medical School,
Clerkship Director, Neurology Clerkship, 07/04-06/07
 5. Rutgers-New Jersey Medical School
Adult Neurology Residency, focus on Demyelinating Illness, Movement Disorders,
Evidence Based Medicine, Systems Based Practice, Fatigue and Ethics, 2 hours per
month,
07/04-present
 6. Rutgers-New Jersey Medical School
Internal Medicine Residency, Neurology for Internist, 2 hours per year
05/14-present
 7. Rutgers-New Jersey Medical School
Neurology Clerkship, Clinical Vignettes, 4.5 hours per year,
07/13-present
 8. Rutgers-New Jersey Medical School
Advanced Physical Diagnosis, Neurologic Examination, 3 hours per year, 01/15-
present
 9. Rutgers-New Jersey Medical School
Mind, Brain and Behavior Course, Auditory System, 1 hour per year
04/05-04/15
 10. Rutgers-New Jersey Medical School
Mind, Brain and Behavior Course, Clinical Correlation Various topics, 4 hours per
year, 04/05-04/15
 11. Rutgers-New Jersey Medical School
Physician Core, Neurologic Examination, 2 hours per year, 01/05-01/14
 12. UMDNJ-New Jersey Medical School
Clinical Neuroscience Course, Headache and Movements Disorders, 3 hours per
year, 10/12-1/13
 13. UMDNJ-New Jersey Medical School
Mind, Brain and Behavior Course, Cranial Nerve Review, 1 hour per year, 04/07-
05/09
 14. UMDNJ-New Jersey Medical School,
Neurology Clerkship Lectures, Core Neurologic Topics, 2 hours per month, 07/04-
05/09
 15. UMDNJ-New Jersey Medical School
Mind, Brain and Behavior Course, Dementia, Integrated Conference
2 hours, 05/06
 16. UMDNJ-New Jersey Medical School

Mind, Brain and Behavior Course, Cranial Nerves, 2 hours, 04/05

B. Research Training

Post Doctoral Fellows: none

Pre Doctoral Students: none

CLINICAL RESPONSIBILITIES:

1. Chief of Service, Department of Neurology
University Hospital, Newark, NJ
08/20-present
2. Director Adult Neurology Clinic
University Hospital, Newark, NJ
07/04-present
3. Attending Physician
General Neurology Service
University Hospital, Newark, NJ
07/04- present
4. Attending Physician
Stroke Service
University Hospital, Newark, NJ
12/04- present
5. Neurologist
Multiple Sclerosis Diagnosis and Treatment Center
Rutgers-NJMS
07/04-present
6. Neurologist
Samuel L. Baily University Huntington's Disease Family Service Center
Rutgers-NJMS, Rutgers-RWJMS and Leisure Chateau Care and Rehabilitation
Center
07/04-present
7. Neurologist
New Jersey Medical School Sarcoidosis Center
Rutgers-NJMS
09/12-present

GRANT SUPPORT:

1. Principal Investigator
 1. F. Hoffmann-La Roche Ltd/Genentech Inc, A randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis, 04/12-present, awarded to date \$677,017
 2. Genentech Inc, An Open-Label Study to Evaluation the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis who Have Had a Suboptimal Response to an Adequate Course of Disease Modifying Treatment, 12/16-03/20, awarded to date \$207,291
 3. Biogen Idec, Inc, A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta 1a) to Natalizumab in Patients with Relapsing Remitting Multiple Sclerosis, 10/10-03/11, \$8,078
 4. Serono, A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS, 03/09-12/10, \$2500
 5. Bayer HealthCare, Real-World Betaseron Outcomes Study (ROBUST), A twelve-month, US prospective, observational, single-arm, multicenter outcomes study of Interferon (Betaseron) given every other day for relapsing multiple sclerosis, 11/07-11/09, \$4,600

6. Acorda Therapeutics, Inc, Open-Label Extension Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Patients with Multiple Sclerosis, who participated in the MS-F204 Trial, 10/07-09/10, \$34,754
 7. Acorda Therapeutics, Inc, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d) in Patients with Multiple Sclerosis, 04/07-12/08, \$39,650
 8. Abbott Laboratories, A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-847 in Subjects with Multiple Sclerosis with a 24-Week Double-Blind Active Extension Phase, 01/05-04/05
2. Co-Investigator
1. Samuel L. Bailey University Huntington's Disease Family Service Center, 07/04-present, 7.25% salary support, PI: Michael K. McCormick, PhD, \$308,000 per year
 2. Theravance Inc. A Phase 3 4- week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in subjects with Primary Autonomic Failure. Protocol Threavance 0169, 10/19-present. PI: Dr. Erin Feinstein
 3. Theravance Inc. A Phase 3 Multicenter, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in subjects with Primary Autonomic Failure. Protocol Threavance 0170, 10/19-present. PI: Dr. Erin Feinstein
 4. Consortium of Multiple Sclerosis Centers (CMSC), North American Registry for Care and Research in Multiple Sclerosis (NARCOMS), 12/16-present. PI: Stephen S. Kamin, MD
 5. Biogen, A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM), 11/14-present, PI: Stephen S. Kamin, MD
 6. CHDI Foundation, Inc., Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort, 10/13-present. PI: Daniel Schneider, MD
 7. National Multiple Sclerosis Society, Grant Number RG7436-A-2, BECOME Long Term Follow Up Study, 1/13-present, PI: Suhayl Dhib-Jalbut, MD, \$243,000
 8. Novartis Pharmaceutical Corporation, Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy, 03/15-02/17 PI: Stephen S. Kamin, MD
 9. HSG, A Randomized, Double Blind, Placebo Controlled Study Of SD-809 Extended Release For The Treatment Of Chorea Associated With Huntington Disease, First Time Use of SD-809 ER in HD (First-HD), 09/13-02/16, PI Daniel Schneider, MD
 10. Novartis Pharmaceuticals Corporation, A 12-month, randomized, rater-and dose-blinded study to compare the efficacy and safety of fingolomod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mh administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis, 04/13-03/16, PI: Stephen S. Kamin, MD, \$18,000
 11. NIH/NINDS, grant number 2R01NS077946, 10/1/12-09/30/17 Site PI: Humberto Marin, MD \$73,683
 12. Biogen Idec, Inc, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis, 09/11-12/14, PI: Stephen S. Kamin, MD, \$5,000
 13. Biogen Idec, Inc, JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering treatment with Tysabri: STRATIFY-2, 02/11-06/15, PI: Stephen S. Kamin, MD, \$10,000.
 14. Actelion Pharmaceuticals Ltd, Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and

- tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis, 03/10-09/11, PI: Stephen S. Kamin, MD, \$51,233
15. Serono, A Phase IIIb, Double Blind, Placebo Controlled Multi-Centre, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing Multiple Sclerosis Who Have Completed Trial 25643, 05/08-01/12, PI: Stuart D. Cook, MD, \$144,000
 16. Serono, A Phase II, Multi-Center, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy with Rebif New Formulation in Multiple Sclerosis Subjects with Active Disease, 03/08-05/12, PI: Stephen S. Kamin, MD, \$166,045
 17. Biogen Idec, TYGRIS: TYSABRI Global Observational Program in Safety, 2/08-present, PI: Stephen S. Kamin, MD, \$33,597
 18. Genzyme Corporation, A Phase 3, Randomized, Rater-and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed On Therapy, 11/07-12/08, PI: Stephen S. Kamin, MD, \$5,000
 19. NIH/NIDS, Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF), 10/05-06/11, PI: Patrick Pullicino, MD, Ph.D.
 20. Co-Investigator, Serono, A Phase III, Randomized, Double Blind, 3 Arm, Placebo Controlled Multi-Centre Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects with Relapsing Multiple Sclerosis, 05/06-05/08
 21. Bayer HealthCare Pharmaceuticals Inc, The BEYOND STUDY: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose, 08/05-01/08, PI: Stuart D. Cook, MD, \$77,800
 22. Bayer HealthCare Pharmaceuticals Inc, Phase IV, Rater-Blinded, Randomized Study, Comparing the Effects of 250 ug of Betaseron with 20 mg of Copaxone in Patients with Relapsing-Remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI with Triple-Dose Gadolinium, 07/05-07/09, PI: Stuart D. Cook, MD, \$1,898,111
 23. Abbott Laboratories, A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-847 in Subjects with Multiple Sclerosis With a 24-Week Double-Blind Active Extension Phase, 05/05-08/05, PI: Stephen S. Kamin, MD, \$3000
 24. Boehringer Ingelheim Pharmaceuticals, Inc, PRoFESS-Prevention Regimen for Effectively avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidrogel & Aspirin, With and Without Micardis, 02/05-10/05, PI: Patrick Pullicino, MD, Ph.D

C. Pending: none

PUBLICATIONS:

- A. Refereed Original Article in Journal
 1. Gajewski M, **Hillen M**, Matassa D, Kunac A, Anana, M, Pompeo L, Kothari N, Murano T. A Comparison of State Medical Licensing Board Disclosures Regarding Resident Performance for United States Allopathic, Osteopathic and Foreign Medical Graduates. JAOA Online First Nov 2020
 2. Bach I, Surathi P, Montealegre N, Abu-Hadid O, Rubenstein S, Redko S, Gupta S, **Hillen M**, Patel P, Khandelwal P, Kamel A. Stroke in COVID-19: a single-centre initial experience in a hotspot of the pandemic. Stroke Vasc Neurol. 2020 Sep 24:svn-2020-000525. Epub ahead of print. PMID: 32973116.
 3. Kumar V, Koul P, Alchaki A, Baisre A, **Hillen ME**. Intraventricular Neurocysticercosis Presenting as Rapidly Progressive Dementia. Infect Dis Diag Treat. 2020 June 4:140 DOI:10.29011/2577-1515.100140

4. Breazzano MP, Shen J, Abdelhakim AH, Dagi Glass L, Horowitz J, Xie SX, De Moraes CG, Chen-Plotkin A, Chen RW, on behalf of the **New York City Residency Program Directors COVID-19 Research Group**. New York City COVID-19 resident physician exposure during exponential phase of pandemic. *J Clin Invest*. 2020 Sep 1;130(9):4720-4733. (Online ahead of print). PMID: 32463802
5. Tajali Y, Ward M, Abraham M, **Hillen M**, Mamoud O, Herschman Y, Mammis A, Pashkover B. Minimally invasive trigeminal ablation (MITA) in multiple sclerosis patients with medically refractory trigeminal neuralgia who are ineligible for intracranial intervention. *J Clin Neurosci*. 2019 Sep 16. S0967-5868(19)30715-5 (Epub ahead of print). PMID: 31537461
6. Murano T, Gajewski M, Anana M, **Hillen M**, Kunac A, Matassa D, Pompeo L, Kothari N. Mandated State Medical Licensing Board Disclosures Regarding Resident Performance. *J Grad Med Educ*. (Epub 2019 May 13). Jun;11(3):307-312 (Epub ahead of print). PMID: 31210862
7. Nisar T, Alchaki A, **Hillen M**. Validation of the ICH Score in a Large Urban Population. *Clin Neurol Neurosurg*. 2018 Nov;174:36-39 (Epub: 2018 Sep 5). PMID: 30205274
8. **Hillen ME**, He W, Al-Qudah Z, Wang W, Hidalgo A, Walia J. Experience in improving door to needle time in a single tertiary stroke center. *J Stroke Cerebrovasc Dis*. 2017 Jul 26;(7):1569-1572 (Epub: 2017 Apr 11). PMID: 28411038
9. Sheikh Z, Anadani N, Raval B, Sharer L, **Hillen M**. Corpus Callosum Lesion with Multiple Strokes. *Neurol* 2017 Apr 4;88(14):e137-e142 PMID: 28373375
10. Hauser SL, Bar-Or A, Comi G, et al; **OPERA I and OPERA II Clinical Investigators**. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med*. 2017 Jan 19;376(3):221-234 (Epub 2016 Dec 21). PMID: 28002679
11. Sheikh Z, Wang R, **Hillen M**. A young man with recurrent coma and refractory status Epilepticus. *JAMA Neurol* 2016 Oct 1;73(10):1243-1244. (Epub: Aug 1, 2016) PMID: 27479548
12. Sheikh Z, Jain S, **Hillen M**. Acute Retinal Necrosis in Multiple Sclerosis: A Neuroimmunologic Challenge! *Neurology* 2016 Mar 8;86(10):972-3. (Epub 2016 Jan 29). PMID 26826206
13. **Hillen ME**, Cook SD, Samanta A, Grant E, Quinless JR, Rajasingham JK. Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis. *Neurol Neuroimmunol Neuroinflamm* 2015 Feb 12;2(2):e72. eCollection 2015 Apr. PMID 25815364
14. Punia V, He W, Agawal N, **Hillen M**. Comparison of neurological healthcare oriented educational resources for patients on the Internet. *J Clin Neurosci* 2014 Dec;21(12):2179-83. (Epub 2014 Sep 4). PMID 25194822
15. Elenein RG, Sharer LR, Cook SD, Pachner AR, Michaels J, **Hillen ME**. A second case of Marburg's variant of multiple sclerosis with vasculitis and extensive demyelination. *Mult Scler*. 2011;17:1531-1538. PMID 21816761
16. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; **MSF204 Investigators**. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. *Ann Neurol*. 2010 Oct;68(4):494-502. PMID 20976768
17. **Hillen ME**, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. *Neurology* 1996 Nov; 47(5): 1180-1183. PMID 8909426
18. **Hillen ME**, Wagner ML, Sage JI. "Subclinical" orthostatic hypotension is associated with dizziness in elderly Parkinson's disease patients. *Arch Phys Med Rehabil* 1996 Jul; 77(7): 710-712. PMID 8670000
19. **Hillen ME**, Sage JI. Proving the worth of neurologists? *Neurology* 1996 Jan; 46: 276-277. PMID 8559403

B. Books, Monographs and Chapters: none

C. Patents Held: none

D. Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional Communications:

1. Medical Editing and Translation in Dutch of the Certifying Exam of the Multiple Sclerosis Nurses International Certifying Board (MSNICB), completed February 2017

E. Abstracts

1. Agin-Liebes J, Hanumanthu R, Toluwalase T, **Hillen M**. Functional Outcome of Post Cardiac Arrest Patients Who Underwent Therapeutic Hypothermia. Accepted at the 2020 American Academy of Neurology (AAN), Toronto, Canada (2020, April). Meeting Cancelled
2. Bouchachi S, **Hillen M**. Should Elderly MS Patients Follow Conventional Dosing of Ocrelizumab? Accepted at the 2020 American Academy of Neurology (AAN), Toronto, Canada (2020, April). Meeting Cancelled
3. Sanghani N, **Hillen M**. First Case of an Anterior Spinal Artery Stroke in Neurosarcoidosis: A case report and review of literature. Accepted at the 2020 American Academy of Neurology (AAN), Toronto, Canada (2020, April). Meeting Cancelled
4. Murano T, **Hillen M**, Kunac A, Matassa D, Gajewski M, Anana M, Pompeo L, Kothari N. Changing the Landscape of Remediation: The Creation And Implementation Of An Institution-Wide Performance Enhancement Program. Presented at the 2020 ACGME Conference; San Diego, CA (2020, February)
5. Tajali Y, Pashkover B, Ward M, Herschman Y, **Hillen M**. Minimally Invasive Trigeminal Ablation (MITA) in Multiple Sclerosis Patients with Medically Refractory Trigeminal Neuralgia (a case series). Presented at the 2019 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); Seattle, WA (2019, May)
6. Tajali Y, Pashkover B, Ward M, Herschman Y, **Hillen M**. A Novel Approach to Treatment of Trigeminal Neuralgia in Multiple Sclerosis Patients using Minimally Invasive Trigeminal Ablation (MITA). Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2019, May)
7. Bach I, Boyanpally A, Reilly S, **Hillen ME**. To CTA or Not to CTA: Should We Continue to Order CT Angiography of Head and Neck in Patients with TIA? Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2019, May)
8. Shapouran S, Hillen M. Late onset Austrian Syndrome in a patient with Bacterial Meningitis. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2019, May)
9. Abu-Hadid O, Hanumanthu R, **Hillen ME**. Immune Reconstitution Inflammatory Syndrome in a newly diagnosed HIV patient with Central Nervous System Tuberculosis. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2019, May)
10. Hanumanthu R, Agin-Liebes J, **Hillen M**, Bhatt A, Olango W. Efficacy of Early Neurological Examination in Determining Survival in Post Cardiac Arrest Patients who Underwent Hypothermia Protocol. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2019, May)
11. Murthy M, **Hillen ME**. First Report of Confirmed CIDP in a Patient with Neuromyelitis Optica Spectrum Disorder (NMOSD). Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2019, May)
12. Sheikh S, Hanumanthu R, **Hillen M**. The Impact of a Dedicated Emergency Department Neurology Resident on the Inpatient Neurology Service. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2019, May)
13. Hanumanthu R, Boyanpally A, Sumicad M, Gomez F, **Hillen M**. Validating the role of Prophylactic Antiepileptic Drugs in Subcortical Intracranial Hemorrhage in a

- Large Urban Hospital. Presented at the American Academy of Neurology (AAN); Los Angeles, CA (2018, April)
14. Walia J, **Hillen M**. The Rutgers-NJMS experience: Why are our Medical Students Increasingly Applying to Adult Neurology? Presented at the American Academy of Neurology (AAN); Los Angeles, CA (2018, April)
 15. Boyanpally A, Hanumanthu R, Sumicad M, Gomez F, **Hillen M**. Validating the role of Prophylactic Antiepileptic Drugs (AED) in Cortical Intracranial Hemorrhage in a Large Urban Hospital. Presented at the American Academy of Neurology (AAN); Los Angeles, CA (2018, April)
 16. **Hillen M**, Kennedy C, McCormack M, Hirapa K, Kneisser E, Fadem B. Gender Affects Factors Associated with Placement into Long Term Care of Patients with Huntington's disease. Presented at the Peter Como Huntington Disease Research Symposium at HSG 2017; Denver, CO (2017, November)
 17. Keller E, McCormack M, **Hillen M**. The Role of CAG repeat size and parental sex in Huntington's Disease. Presented at the Peter Como Huntington Disease Research Symposium at HSG 2017; Denver, CO (2017, November)
 18. Kennedy C, McCormack M, **Hillen M**, Hirapa K, Kneisser E, Fadem B, Okeorji C. Progression of Huntington's Disease and Time when Interventions Could Be Most Effective. Presented at the New York Academy of Sciences (NYAS); New York, NY (2017, June)
 19. Alchaki AR, Nisar T, Guzman D, Sugalski G, **Hillen ME**. Fatal Case of Thyrotoxic Periodic Paralysis, Presenting as Hyperacute Paralysis and Cardiac Arrhythmia. Presented at the American Academy of Neurology (AAN); Boston, MA (2017, April)
 20. Shivamurthy VK, Alchaki A, Anadani N, **Hillen ME**. Rapidly Progressive Dementia due to a Single Intraventricular Neurocysticercosis Cyst. Presented at the American Academy of Neurology (AAN); Boston, MA (2017, April)
 21. Alchaki AR, Gomez F, El-Ghanem M, Han H and **Hillen ME**. Usefulness of CT Angiography in the Diagnosis and Treatment of Intracranial Hemorrhage. Presented at the American Academy of Neurology (AAN); Boston, MA (2017, April)
 22. Olango W, Gromko L, Jaker M, **Hillen M**. Presented at the 2016 Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC); National Harbor, MD (2016, June)
 23. Olango W, **Hillen M**. Paroxysmal Kinesogenic Dyskinesias As a Presenting Symptom of Neuromyelitis Optica. Presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); National Harbor, MD (2016, June)
 24. Anadani N, El-Ghanem M, Nuoman R, Hidalgo A, **Hillen M**. Simultaneous Occurrence of Leptomeningitis, Basilar Meningitis and Cauda Equina Syndrome Due to Varicella Zoster Virus in an HIV patient. Presented at the American Academy of Neurology (AAN); Vancouver, Canada (2016, April)
 25. Wang W, Raval B, **Hillen M**. Acute Korsakoff's Syndrome following a Subcallosal Artery Stroke. Presented at the 2015 American Neurological Association (ANA); Chicago, IL (2015, September)
 26. Sheikh Z, Wang W, Raval B, Olango W, **Hillen M**. Tumefactive Demyelinating Lesion (TDL) of Spinal Cord Due to Aquaporin-4 Antibody. Presented at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); Indianapolis, IN (2015, May)
 27. Segal D, Sheikh S, Shahbahrami K, Garikparthy J, Monserrate A, Tentler A, **Hillen M**, Shih LY, Pletcher B. An Adult Presenting with Neurological Symptoms Attributed to Hyperhomocysteinemia that Resolved with Treatment. Presented at the American Academy of Neurology (AAN); Washington, DC (2015, April)
 28. He W, Al-Qudah Z, Wang W, Tank V, **Hillen M**. Long Term Impact of Implementation of a Stroke Protocol on Door to Needle Time in Administration of Intravenous Recombinant Tissue Plasminogen Activator (IV-tPA). Presented at the American Academy of Neurology (AAN); Washington, DC (2015, April)

29. Kornitzer J, **Hillen M**, Hayes-Rosen C, Hidalgo A, He W. Is Clinical Neurology Exposure Increasing in Medical Schools Throughout the United States? Presented at the American Academy of Neurology (AAN); Washington, DC (2015, April)
30. Raval B, El-Ghanem M, **Hillen M**. Late onset MELAS, presenting as non-convulsive status and atypical stroke. Presented at the American Academy of Neurology (AAN); Washington, DC (2015, April)
31. Chen A, **Hillen M**. Intraventricular Blood and Pneumocephalus After Epidural Blood Patch. Presented at the American Academy of Neurology (AAN); Washington, DC (2015, April)
32. Raval B, Rayi A, Jacob M, **Hillen M**. Delay of Percutaneous Gastrostomy Tube (PEG) Placement in Patients with Ischemic Stroke in a Large Urban Hospital. Presented at the American Academy of Neurology (AAN); Washington, DC (2015, April)
33. El-Ghanem M, **Hillen ME**. Atypical Postpartum Reversible Cerebral Vasoconstriction Syndrome with Extracranial Cerebral Artery Stenosis. Presented at the New Jersey State Stroke Conference; New Brunswick, NJ (2015, April)
34. Raval B, El-Ghanem M, **Hillen M**. Late onset MELAS, presenting as non-convulsive status and atypical stroke. Presented at the New Jersey State Stroke Conference; New Brunswick, NJ (2015, April)
35. Raval B, Rayi A, Jacob M, **Hillen M**. Delay of Percutaneous Gastrostomy Tube (PEG) Placement in Patients with Ischemic Stroke in a Large Urban Hospital. Presented at the New Jersey State Stroke Conference; New Brunswick, NJ (2015, April)
36. **Hillen M**, Amin R, Kennedy C, McCormack M. Do bad habits prevent manifestations of Huntington's Disease? Presented at the Eighth Annual Huntington Disease Clinical Research Symposium (HDCRS); Minneapolis, MN (2014, November)
37. Raval B, El-Ghanem M, **Hillen M**. Late onset MELAS, presenting as non-convulsive status and atypical stroke. Presented at the American Neurologic Association (ANA); Baltimore, MD (2014, October)
38. Jin K, Segal D, **Hillen ME**. An unusual case of neurofibromatosis type 1, high titer antinuclear autoantibodies and neuromyelitis optica. Presented at the 2014 Joint ACTRIMS-ECTRIMS Meeting; Boston, MA (2014, September)
39. Georgsson H, Punia V, El-Ghanem M, **Hillen ME**. Adherence with post-stroke follow-up clinic visits and factors influencing compliance in a large urban hospital in the United States of America. Presented at the EFNS-ENS Joint Congress of European Neurology; Istanbul, Turkey (2014, May)
40. Bhat A, **Hillen M**. Atypical Presentation of Posterior Reversible Encephalopathy Syndrome. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2014, May)
41. Sivaraju A, Punia V, **Hillen M**. Life Threatening Intracranial Hemorrhage as a Consequence of Dobutamine Stress Echocardiography: A Case Report. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2014, April)
42. El-Ghanem M, Jin P, Punia V, He W, **Hillen M**. Adherence with Post-stroke Follow-up Clinic Visits and Factors Influencing Compliance in a Large Urban Hospital. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2014, April)
43. Georgsson H, Bhat A, **Hillen M**. Cerebral Venous Congestion Caused By Cervical Arteriovenous Fistula: A Rare Delayed Complication Following Heart Transplantation. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2014, April)
44. Dagar A, Punia V, Agarwal N, He W, **Hillen ME**. Comparison of American Academy of Neurology's online patient education materials to other common Internet sources. Presented at the American Academy of Neurology (AAN); Philadelphia, PA (2014, April)
45. Punia V, El-Ghanem M, Jin P, He W, **Hillen M**. Adherence with Post-stroke Follow-up Clinic Visits and Factors Influencing Compliance in a Large Urban Hospital.

- Presented at the New Jersey State Stroke Conference; New Brunswick, NJ (2014, April)
46. El-Ghanem MH, Dagar A, Agarwal N, Punia V, **Hillen ME**. Comparison of various online patient education materials (PEMs) for neurological diseases. Presented at the American Neurological Association (ANA); New Orleans, LA, USA (2013, October)
 47. El-Ghanem MH, Punia V, **Hillen ME**. Adherence with Post-stroke Follow-up Clinic Visits and Factors Influencing Compliance in a Large Urban Hospital. Presented at the American Neurological Association (ANA); New Orleans, LA, USA (2013, October)
 48. McCormack MK, Kennedy CA, Martino C. **Hillen ME**, Hogan C, Alterman, N, Marin H, Schneider D, Forsberg M. A Multigenerational and Interprofessional Approach to Alleviating Health Disparities in Racially Diverse Populations with Huntington Disease. Presented at the 2nd Annual Conference to Eliminate Health Disparities in Genomic Medicine ; San Francisco, CA, USA (2013, May)
 49. Jin Y, Punia V, **Hillen ME**, Souayah N, Michaels J. HIV Seroconversion, Quadriplegia and Neuropathy. Presented at 35th Annual Carrell-Krusen Neuromuscular Symposium; Dallas, TX, USA (2013, February)
 50. Rajasingham JK, Cook SD, Samanta A, Grant E, Quinless JR, **Hillen ME**. Fatal Acute Liver Failure with Hepatitis B Virus infection during Natalizumab Treatment in Multiple Sclerosis. Presented at Americas Committee for Treatment and Research on Multiple Sclerosis (ACTRIMS); San Diego, California, USA (2012, May)
 51. Elenein, RA, Sharer L, Cook S, Pachner A, Michaels J, **Hillen M**. Second Case of Marburg's Variant of MS with Vasculitis and Extensive Demyelination. Presented at American Academy of Neurology (AAN); Honolulu, Hawaii, USA. (2011, April)
 52. Kennedy CA, Fadem B, **Hillen ME**, Hidalgo A. Interdisciplinary Integration of Pre-Clinical and Clinical Psychiatric Medical School Curriculum. Presented at the 36th Annual Meeting of the Association of Directors of Medical Student Educators in Psychiatry (ADMSEP); Jackson Hole, Wyoming, USA. (2010, June)

F. Reports: none

PRESENTATIONS:

A. Scientific: none

B. Professional:

1. Invited Speaker, University of Louisville Department of Neurology, Internet Live Course Webinar during Covid19 pandemic. 12th Annual Advances in Neurology: Staying up to Date with Advances in the Management of Multiple Sclerosis. 5/15/2020
2. Grand Rounds, Robert Wood Johnson University Hospital, Rahway, NJ. Effective Management of Multiple Sclerosis: Shared Decision-Making with the Patient, 4/3/2019
3. Grand Rounds, Nathan Littauer Hospital, Gloversville, NY. Effective Management of Multiple Sclerosis: Shared Decision-Making with the Patient, 3/8/2019
4. Invited Speaker, Consortium of Multiple Sclerosis Centers, Nashville, TN. Achieving New Treatment Goals in Multiple Sclerosis: Strategies for Initial Treatment Selection and Patient Engagement, 5/31/2018
5. Clinical Pathological Conference, Department of Internal Medicine, Rutgers-NJMS, Newark, NJ. Miller Fischer Syndrome, 11/3/2016
6. Clinical Pathological Conference, Department of Internal Medicine, Rutgers-NJMS, Newark, NJ. Autonomic Failure, 2/4/2016
7. Key Note Speaker, Preceptor Recognition Dinner-UMDNJ School of Nursing, Iselin, NJ. First Steps to Take Before You Refer to a Neurologist, 06/05/2013

8. Grand Rounds, Division of Neurology, LeHigh Valley Hospital, Allentown, PA. Inflammatory Disorders of the Brain, a Case Based Approach, 05/30/2013
9. Grand Rounds, Department of Emergency Medicine, UMDNJ-NJMS, Newark, NJ, An approach to Neurologic Problems in the Emergency Room, 03/27/2013
10. Chief Resident Work Shop, UMDNJ-NJMS, Newark, NJ, Management 101, 05/14/12
11. Grand Rounds, Department of Psychiatry, UMDNJ-RWJ, Piscataway, NJ, Huntington's Disease, 11/3/11
12. Key Note Speaker, American Medical Women's Association, UMDNJ-NJMS, Newark, NJ, 03/15/10
13. Grand Rounds, Department of Neurology and Neuroscience, UMDNJ-NJMS, Newark, NJ, Huntington's Disease, 12/03/08
14. Grand Rounds, Department of Obstetrics and Gynecology, UMDNJ-NJMS, Newark, NJ, Common Neurologic Problems in Pregnancy, 10/08/08